Harpreet Kaur, medical superintendent, head , Lab Services and Blood Centre, Aakash Healthcare in Delhi, said, “The process of production of the product involves multiple viral inactivation processes, and the blood products undergo testing at the donor level and pre-processing. The second testing causes delays and adds to the cost of production. India still imports more than 60% of plasma-derived products, so rational and cost-efficient manufacturing will help support domestic manufacturers, which in turn will improve availability of immunoglobulins, clotting factors and other essential therapies.
